Dr Richard Bourne, Associate Professor in the School of Chemical and Process...
Dr Richard Bourne, Associate Professor in the School of Chemical and Process Engineering.
Source: University of Leeds

‘Lab-bot’ could revolutionise drug development

A robot-controlled laboratory where decisions are made by artificial intelligence will change the way new drugs are discovered. Dr Richard Bourne, Associate Professor in the School of Chemical and Process Engineering, the engineer leading the project to develop a prototype “lab-bot” says it will reduce the time it takes to identify and synthesise molecules for new medicines – a process that can take years as scientists refine the shape and property of target molecules.

In some cases, chemists have to test a million molecules before finding the right one. Bourne says the initial aim of the project is to find medicinally-active chemicals that can be used to treat arthritis and cancer. “This technology has the potential to fundamentally change the way drugs are discovered. Discovery chemists are involved in a ceaseless challenge to synthesise new drug molecules to the point where they can be successfully tested for medical activity. But the process of reaching that point can be very slow, and that has consequences for people who are waiting for new drugs that could help alleviate painful and chronic conditions. If the process is rushed, then the new treatments may not be developed and new types of molecule will not be evaluated,” he explained. “Our research at Leeds is about finding a balanced approach, so new molecules are found that are safe and reliable but are discovered in a timely manner. We believe by harnessing artificial intelligence we can achieve that accelerated approach.”

Professor Karen Holford, Chair of the academy’s Research Committee, said: “I am delighted to welcome these leading researchers to join us. Working closely with their industrial partners, each awardee will establish a world-leading research group in their field of engineering that will ultimately help to generate real economic benefits.”

Dr Bourne’s team is collaborating with a number of pharmaceutical companies including AstraZeneca, Pfizer and GSK. Modern drug discovery involves synthesising compounds that can act on diseases at a molecular level, perhaps by blocking proteins that are harmful. In a suite of laboratories, Dr Bourne and his colleagues are optimising the drug discovery process by bringing together machine learning, automation and an idea called continuous flow chemistry.

The result is a robot-controlled system that can autonomously change the parameters of a reaction until the optimal or best results are achieved. In flow chemistry, reactions take place in narrow pipes rather than a traditional laboratory flask or reactor. In the system at Leeds, the reaction is contained in pipes that are smaller than a millimetre in diameter – making it possible to have greater control of the reactants.

An artificial intelligence system continuously monitors the outcome of the reactions, compares the results from other experiments held in an online database and then alters the parameters – such as temperature or pressure – until the optimal result is achieved. The approach is not only about discovery chemistry. The aim is that the approach could be scaled up and run by “production robots” for manufacture. “Lab-bots” have been used at Leeds in recent years to optimise the synthesis of a cancer drug called Osimertinib, which was developed by AstraZeneca.

The robotic laboratory was able to identify the optimum manufacturing process after a run time of 26 hours. In comparison, the conventional approach would have taken scientists around two weeks of intense laboratory experimentation.

Subscribe to our newsletter

Related articles

Robotic testing platform increases coronavirus testing capacity

Robotic testing platform increases coronavirus testing capacity

A robotic testing platform developed in just nine days by dementia researchers could substantially increase the UK’s capacity to test people for coronavirus.

A robotic COVID-19 testing lab

A robotic COVID-19 testing lab

Scientists are creating from scratch a diagnostic lab with the capability to process more than 1,000 patient samples per day.

Smart insoles unlock the secrets of your sole

Smart insoles unlock the secrets of your sole

Researchers at Stevens Institute of Technology have developed an AI-powered, smart insole that instantly turns any shoe into a portable gait-analysis laboratory.

Robot uses AI and imaging to draw blood

Robot uses AI and imaging to draw blood

Engineers have created a tabletop device that combines a robot, AI and near-infrared and ultrasound imaging to draw blood or insert catheters to deliver fluids and drugs.

University starts drone transport program with UPS, Matternet

University starts drone transport program with UPS, Matternet

Drone service slated to begin February 2020, with goals of enhancing efficacy, reliability and predictability of delivering medical products between hospitals and laboratories.

Smart microscope adapts to diagnose infectious diseases

Smart microscope adapts to diagnose infectious diseases

Using machine learning, a prototype microscope teaches itself the best illumination settings for diagnosing malaria.

Retinal screening in diabetes: diagnosis by robot

Retinal screening in diabetes: diagnosis by robot

Physicians have been using automatic digital retinal screening, without assistance from an ophthalmologist, to detect diabetic retinal disease.

Microscopy: AI converts 2D images into 3D

Microscopy: AI converts 2D images into 3D

Researchers have devised a technique that extends the capabilities of fluorescence microscopy, which allows scientists to precisely label parts of living cells and tissue with dyes that glow under special lighting.

Robotic hand merges amputee and robotic Control

Robotic hand merges amputee and robotic Control

Scientists have successfully tested neuroprosthetic technology that combines robotic control with users’ voluntary control, opening avenues in the new interdisciplinary field of shared control for neuroprosthetic technologies.

Popular articles